Showing 4031-4040 of 5771 results for "".
- Visus Therapeutics Expands Ophthalmic Drug Portfolio With Investigational Therapies for Glaucoma and AMDhttps://modernod.com/news/visus-therapeutics-expands-ophthalmic-drug-portfolio-with-investigational-therapies-for-glaucoma-and-amd/2479457/Visus Therapeutics announced it has entered into a worldwide exclusive licensing agreement with Cella Therapeutics to develop an array of investigational ophthalmic therapies to treat glaucoma and age-related macular degeneration (AMD). The company also announced a worldwide exclusive licensing a
- Harrow Health Acquires Ophthalmic Surgical Drug Candidate From Wakamoto Pharmaceuticalhttps://modernod.com/news/harrow-health-acquires-ophthalmic-surgical-drug-candidate-from-wakamoto-pharmaceutical/2479455/Harrow Health announced that it has entered into an agreement with Tokyo, Japan-based Wakamoto Pharmaceutical to acquire the U.S. and Canadian commercial rights for drug candidate MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection. MAQ-
- Journal Highlights Desirable PK/PD Profiles of THR-687 and THR-149https://modernod.com/news/journal-highlights-desirable-pk-pd-profiles-of-thr-687-and-thr-149/2479450/Oxurion NV announced the publication of two related papers in the Journal of Pharmacokinetics and Pharmacodynamics entitled “Systemic exposure following intravitreal administration of therapeutic agents: an integrated pharmacokinetic approach.” These papers describe the pharmacoki
- Alcon to Launch TOTAL30 as the First Monthly Replacement, Water Gradient Contact Lenshttps://modernod.com/news/alcon-to-launch-total30-as-the-first-monthly-replacement-water-gradient-contact-lens/2479449/Alcon announced plans to launch TOTAL30, the first-and-only monthly replacement, water gradient lens. Using Alcon’s proprietary water gradient material first introduced with DAILIES TOTAL1 contact lenses, TOTAL30 delivers a premium wearing experience for reusable contact lens wearers, according t
- Oculus Receives FDA Clearance for the Myopia Masterhttps://modernod.com/news/fda-clearance-for-the-new-oculus-myopia-master/2479444/Oculus announced that it has received FDA 510(k) clearance for the Myopia Master, which combines axial length, refraction values, and the central corneal radii measurements. The quick, contactless measurement method for axial length is not influenced by the accommodation status of the eye
- Sydnexis Secures $45 Million Series B Financing to Advance Myopia Drug Candidatehttps://modernod.com/news/sydnexis-secures-45-million-series-b-financing/2479442/Sydnexis announced the completion of a $45 million Series B financing to fund Sydnexis’ lead candidate, SYD-101, through completion of the fully enrolled pivotal Phase 3 STAAR study for the treatment of progressive myopia in children. The financing was led by Visionary Ventures, Blue Stem
- Regeneron Terminates Ocular Therapeutix Collaboration to Develop a Sustained-Release Formulation of Aflibercepthttps://modernod.com/news/regeneron-terminates-ocular-therapeutix-collaboration-to-develop-a-sustained-release-formulation-of-aflibercept/2479441/Ocular Therapeutix announced that Regeneron has terminated the option and license agreement collaboration between the companies. The termination became effective August 5, 2021. The collaboration with Regeneron was initially formed in 2016 for the development and commercialization of produ
- Visus Therapeutics to Host First Capital Markets Day in New York Cityhttps://modernod.com/news/visus-therapeutics-to-host-first-capital-markets-day-in-new-york-city/2479439/Visus Therapeutics announced that the company will host its first Capital Markets Day for investors, analysts, and media on August 31, 2021, from 10 am to 2 pm ET at Convene, 530 Fifth Avenue in New York City. During the Capital Markets Day, members of Visus’ leadership team and leading ey
- Eyevensys Raises $12M in a Series B Plus Funding Roundhttps://modernod.com/news/eyevensys-raises-12m-in-a-series-b-plus-funding-round/2479435/Eyevensys announced it has raised $12 million in a Series B Plus funding round. Korea Investment Partners is leading the Series B Plus financing and existing investors will also join the round. The financing will support Eyevensys’ accelerated development of its EYS809 program for the tr
- Aldeyra Therapeutics Receives Orphan Drug Designation from the FDA for ADX-2191 to Treat Retinitis Pigmentosahttps://modernod.com/news/aldeyra-therapeutics-receives-orphan-drug-designation-from-the-fda-for-adx-2191-to-treat-retinitis-pigmentosa/2479434/Aldeyra Therapeutics announced that the FDA has granted orphan drug designation for ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa (RP). Methotrexate inhibits dihydrofolic reductase, an enzyme involved in cellular replication and activation. In